Our results primarily confirm that patients with ER+/PgR-/HER2- tumours display more unfavourable clinicopathologic characteristics compared with patients with ER+/PgR+/HER2- tumours, which affirms the prognostic importance of PgR expression. This evidence concerns the gene ERBB2 and neoplasm.